Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $12.90. Insider activity concern — blocks BUY_NOW at $15.19. Engine's entry $12.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: sole-source contract manufacturers.
Aurinia is a biopharmaceutical company focused on autoimmune diseases, commercializing LUPKYNIS (voclosporin) — the first FDA-approved oral therapy for lupus nephritis — in the US directly and via Otsuka for Japan, EU, UK and Switzerland. Net product sales were $271.3 million in... Read more
Wait for pullback to $12.90. Insider activity concern — blocks BUY_NOW at $15.19. Engine's entry $12.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: sole-source contract manufacturers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Fundamentals strong but target reached (-2.9% upside). Wait for pullback. Score 7.3/10, moderate confidence.
Passes 4/6 gates (positive momentum, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductLUPKYNIS10-K Item 1A: 'The success of our business is substantially dependent on our ability to successfully commercialize LUPKYNIS, our sole approved product.'
- HIGHSuppliersole-source contract manufacturers10-K Item 1A: 'We rely on sole-source contract manufacturers to produce LUPKYNIS and clinical drug supply and expect to continue to do so to meet our commercial and development needs.'
- MEDIUMCustomerOtsuka10-K Item 1A: 'if Otsuka is unable to successfully commercialize oral voclosporin in the Otsuka Territories, the commercial prospects for LUPKYNIS in the Otsuka Territories will be limited'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMKevin Tang appointed as CEO of Aurinia effective March 23, 2026, succeeding as principal executive officer. Tang, age 59, previously served as Chair since 2024 and is President of Tang Capital Management. No disagreement with company cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 ceiling hits
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $12.90. Insider activity concern — blocks BUY_NOW at $15.19. Engine's entry $12.90 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: sole-source contract manufacturers. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Fundamentals strong but target reached (-2.9% upside). Wait for pullback. Target $16.54 (+8.9%), stop $11.54 (−31.6%), Setup A.R:R 2.4:1. Score 7.3/10, moderate confidence.
Take-profit target: $16.54 (+12.2% upside). Target $16.54 (+8.9%), stop $11.54 (−31.6%), Setup A.R:R 2.4:1. Stop-loss: $11.54.
Concentration risk — Product: LUPKYNIS; Concentration risk — Supplier: sole-source contract manufacturers; Cyclical risk: PE expanding 2.3x (earnings normalizing).
Aurinia Pharmaceuticals Inc trades at a P/E of 7.1 (forward 16.1). TrendMatrix value score: 7.1/10. Verdict: Buy (Wait for Entry).
13 analysts cover AUPH with a consensus score of 3.9/5. Average price target: $17.
What does Aurinia Pharmaceuticals Inc do?Aurinia is a biopharmaceutical company focused on autoimmune diseases, commercializing LUPKYNIS (voclosporin) — the...
Aurinia is a biopharmaceutical company focused on autoimmune diseases, commercializing LUPKYNIS (voclosporin) — the first FDA-approved oral therapy for lupus nephritis — in the US directly and via Otsuka for Japan, EU, UK and Switzerland. Net product sales were $271.3 million in 2025, up 25% year-over-year. LUPKYNIS is the company's sole approved product.